Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1967 | 3 |
| 1969 | 1 |
| 1970 | 6 |
| 1971 | 1 |
| 1972 | 2 |
| 1975 | 3 |
| 1976 | 2 |
| 1977 | 2 |
| 1978 | 2 |
| 1979 | 7 |
| 1980 | 3 |
| 1981 | 2 |
| 1982 | 2 |
| 1983 | 3 |
| 1984 | 3 |
| 1985 | 1 |
| 1986 | 5 |
| 1987 | 3 |
| 1988 | 3 |
| 1989 | 6 |
| 1990 | 7 |
| 1991 | 5 |
| 1992 | 6 |
| 1993 | 4 |
| 1994 | 9 |
| 1995 | 5 |
| 1996 | 10 |
| 1997 | 3 |
| 1998 | 8 |
| 1999 | 2 |
| 2000 | 3 |
| 2001 | 4 |
| 2002 | 3 |
| 2003 | 5 |
| 2004 | 3 |
| 2005 | 6 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 5 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 2 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 8 |
| 2023 | 2 |
| 2024 | 2 |
Search Results
184 results
Results by year
Page 1
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
Eur Urol. 2024 Mar;85(3):274-282. doi: 10.1016/j.eururo.2023.05.009. Epub 2023 Jun 2.
Eur Urol. 2024.
PMID: 37271630
Clinical Trial.
[Recent advances in patient-related outcome in gynaecological cancer].
Bull Cancer. 2014 Jul-Aug;101(7-8):756-9. doi: 10.1684/bdc.2014.1938.
Bull Cancer. 2014.
PMID: 25025654
Review.
French.
[Repair].
Rev Neurol (Paris). 2002 Dec;158 Spec no 1:S49-55.
Rev Neurol (Paris). 2002.
PMID: 12690664
Review.
French.
Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.
Cancer Med. 2021 Sep;10(18):6304-6309. doi: 10.1002/cam4.4172. Epub 2021 Aug 12.
Cancer Med. 2021.
PMID: 34382352
Free PMC article.
Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: Methodology of clinical trials and clinical benefit.
Cancer Treat Rev. 2017 Feb;53:53-60. doi: 10.1016/j.ctrv.2016.12.003. Epub 2016 Dec 30.
Cancer Treat Rev. 2017.
PMID: 28073101
Review.
Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study.
Lancet Healthy Longev. 2022 Mar;3(3):e176-e185. doi: 10.1016/S2666-7568(22)00002-2. Epub 2022 Feb 4.
Lancet Healthy Longev. 2022.
PMID: 36098291
Free article.
Clinical Trial.
Impact of automated methods for quantitative evaluation of immunostaining: Towards digital pathology.
Front Oncol. 2022 Oct 11;12:931035. doi: 10.3389/fonc.2022.931035. eCollection 2022.
Front Oncol. 2022.
PMID: 36303844
Free PMC article.
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
Gynecol Oncol. 2022 Sep;166(3):389-396. doi: 10.1016/j.ygyno.2022.06.022. Epub 2022 Jul 26.
Gynecol Oncol. 2022.
PMID: 35902297
Clinical Trial.
Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma.
Gynecol Oncol. 2023 Feb;169:78-84. doi: 10.1016/j.ygyno.2022.11.029. Epub 2022 Dec 13.
Gynecol Oncol. 2023.
PMID: 36521352
Cite